[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547581":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":31,"responsibleParty":59,"collaborators":64,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":10,"enrollmentInfo":109,"targetDuration":112,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"University of Florence","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Episodic migraine",null,"Patients affected by an episodic pattern migraine(\\\u003C 15 monthly headache days) with or without aura according to ICHD-III criteria.",[13],"Drug: Rimegepant 75 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Rimegepant 75 mg","Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention",[9],[21],"Rimegepant",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Luigi F Iannone, MD","CONTACT","+393896969606","luigifrancesco.iannone@unimore.it",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Roberto De Icco, MD","roberto.deicco@mondino.it",[32,48],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi","RECRUITING","Florence","50134","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],11.24626,43.77925,{"lat":43,"lon":42},[46],{"name":24,"role":25,"phone":10,"phoneExt":10,"email":47},"luigifrancesco.iannone@unifi.it",{"facility":49,"status":34,"city":50,"state":50,"zip":51,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"IRCCS National Neurological Institute \"C. Mondino\" Foundation","Pavia","27100",{"type":40,"coordinates":53},[54,55],9.15917,45.19205,{"lat":55,"lon":54},[58],{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":63,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Luigi Francesco Iannone","Researcher","University of Modena and Reggio Emilia",[65,66,68,70,72,74,76,79,81,83,85,87,89,91,93,95,97],{"name":49,"class":6},{"name":67,"class":6},"Società Italiana per lo Studio delle Cefalee",{"name":69,"class":6},"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari",{"name":71,"class":6},"Università degli Studi dell'Aquila",{"name":73,"class":6},"University of Roma La Sapienza",{"name":75,"class":6},"Azienda Ospedaliero Universitaria Policlinico Modena",{"name":77,"class":78},"Ospedale di Piove di Sacco","UNKNOWN",{"name":80,"class":6},"Azienda Ospedaliero-Universitaria di Parma",{"name":82,"class":6},"Azienda Ospedaliera S. Maria della Misericordia",{"name":84,"class":6},"A.O.U. Città della Salute e della Scienza",{"name":86,"class":6},"Cliniche Humanitas Gavazzeni",{"name":88,"class":6},"University of Campania Luigi Vanvitelli",{"name":90,"class":6},"Ospedale Santo Stefano",{"name":92,"class":6},"Azienda Policlinico Umberto I",{"name":94,"class":6},"Auxologico San Luca",{"name":96,"class":6},"Asst Degli Spedali Civili Di Brescia",{"name":98,"class":6},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","100547581","rimegepant-effectiveness-and-tolerability-as-migraine-preventive-treatment-100547581",false,"NCT06409832","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment","RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)","RAISE","Inclusion Criteria:\n\n* Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);\n* At least 4 monthly migraine days;\n* Good compliance to study procedures;\n* Availability of headache diary at least of the preceding months before enrollment.\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Diagnosis of chronic migraine\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.\n* Changes in preventive treatments in the month before the first administration of rimegepant","ALL","18 Years",{"count":110,"type":111},100,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.",[116,117,118],"Migraine","Migraine With Aura","Migraine Without Aura",[120,121,122,123,124,21],"Headache","Medication overuse headache","Pain","Migraine prevention","Gepant","2026-06-09",{"date":127,"type":128},"2026-06-11","ACTUAL",{"date":130,"type":128},"2024-03-26",{"date":132,"type":111},"2027-09",{"name":5,"class":6},2]